US WorldMeds said the FDA has converted TECELRA (afamitresgene autoleucel) to full approval and expanded its indication to include pediatric patients as young as 12 years old with unresectable or metastatic synovial sarcoma. The engineered T‑cell therapy is now indicated for patients 12 and older who have received prior chemotherapy, are HLA‑A02:01P, ‑A02:02P, ‑A02:03P or ‑A02:06P positive, and whose tumors express the MAGE‑A4 antigen as determined by FDA‑approved or cleared companion diagnostic tests. TECELRA is administered as a single infusion and became the first engineered T‑cell therapy for a solid tumor to receive accelerated FDA approval in August 2024.
The latest FDA action both confirms the therapy’s benefit–risk profile and extends access beyond adults to eligible adolescents with advanced synovial sarcoma, a population with limited treatment options. Company executives noted that the move from accelerated to full approval is supported by additional clinical evidence, which they said may help inform decisions by physicians, patients and families. The expansion to include 12‑ to 17‑year‑olds allows clinicians to apply the same engineered T‑cell approach in younger biomarker‑defined patients that has been available in adults.
TECELRA is a personalized therapy in which a patient’s own T cells are engineered to recognize and attack tumor cells expressing the MAGE‑A4 antigen in the context of specific HLA‑A*02 alleles. Until the new decision, this modality had only been accessible to adult patients in the U.S. The expanded indication now offers an additional option for adolescents with biomarker‑eligible, unresectable or metastatic synovial sarcoma who have already received chemotherapy and have few alternative therapies.
The full approval and label expansion are based on data from the open‑label, single‑arm SPEARHEAD‑1 study, which enrolled 137 patients across three cohorts. The primary efficacy endpoint was overall response rate as assessed by independent review, supported by duration of response. TECELRA achieved an overall response rate of 43.8%, including a 3.6% complete response rate. Median duration of response was 5.3 months (95% CI: 4.5–8.2), and among responders, 31.9% maintained a response for 24 months or longer. Investigators said the availability of an engineered cell therapy for adolescents allows pediatric and adolescent oncology teams to integrate this option into treatment planning using the same evidence base that has guided adult care in advanced synovial sarcoma.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!